ASH Clinical News ACN_4.12_Full book Web | Page 30

You Make the Call: Meeting on Hematologic Malignancies Edition
The American Society of Hematology’s 2018 Meeting on Hematologic Malignancies (MHM), held
September 7-8 in Chicago, featured experts sharing insights into the treatment of leukemia,
lymphoma, myelodysplastic syndromes, myeloma, and myeloproliferative neoplasms.
The MHM program content was structured as “How I Treat” presentations that showcased each
speaker’s treatment approaches. During their presentations, the experts asked the audience
how they would respond to challenging patient cases, with audience members voting live at
the meeting via an audience response system, but we wanted to know what our readers
would do.
See below for a comparison between audience members’ and ASH Clinical News
readers’ responses to the three questions we shared via email during the meeting.
Thank you to everyone who participated!
Left to right: lymphoma cells,
myeloma cells, leukemia cells
Anjali Advani, MD
How I Treat Patients With Newly Diagnosed and Relapsed Acute Lymphocytic Leukemia
A 20-year-old man presents with a two-week history of fatigue, bleeding, and low-grade fevers.
His lab results showed the following: white blood cells 2×10 9 /L, hemoglobin 6.0 g/dL,
and platelets 20×10 9 /L. A bone marrow aspirate and biopsy show 70 percent blasts and
was positive for CD10, CD19, TdT, and CD34 (but negative for CD20), consistent with
pre–B-cell ALL.
How would you treat this patient?
A. A pediatric-based regimen (i.e., the C10403 protocol
[vincristine, daunorubicin, pegaspargase, prednisone])
B. Hyper-CVAD (cyclophosphamide, vincristine,
doxorubicin, dexamethasone, methotrexate, cytarabine)
AUDIENCE
RESPONSE ASH
CLINICAL NEWS
READERS’
RESPONSE
A. 80%
B. 8%
C. 12% A. 91%
B. 0%
C. 9%
C. CALGB 19802 regimen (cyclophosphamide,
daunorubicin, vincristine, prednisone, L-asparaginase)
28
ASH Clinical News
October 2018
ASH